As of 2025-12-29, the EV/EBITDA ratio of Syros Pharmaceuticals Inc (SYRS) is 0.18. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SYRS's latest enterprise value is -17.18 mil USD. SYRS's TTM EBITDA according to its financial statements is -95.71 mil USD. Dividing these 2 quantities gives us the above SYRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.7x - 15.3x | 14.0x |
| Forward P/E multiples | 16.1x - 22.2x | 19.2x |
| Fair Price | (13,311.82) - (12,642.90) | (13,708.99) |
| Upside | -11358310.3% - -10787559.0% | -11697194.0% |
| Date | EV/EBITDA |
| 2025-12-26 | 0.18 |
| 2025-12-24 | 0.18 |
| 2025-12-23 | 0.18 |
| 2025-12-22 | 0.18 |
| 2025-12-19 | 0.18 |
| 2025-12-18 | 0.18 |
| 2025-12-17 | 0.18 |
| 2025-12-16 | 0.18 |
| 2025-12-15 | 0.18 |
| 2025-12-12 | 0.18 |
| 2025-12-11 | 0.18 |
| 2025-12-10 | 0.18 |
| 2025-12-09 | 0.18 |
| 2025-12-08 | 0.18 |
| 2025-12-05 | 0.18 |
| 2025-12-04 | 0.18 |
| 2025-12-03 | 0.18 |
| 2025-12-02 | 0.18 |
| 2025-12-01 | 0.18 |
| 2025-11-28 | 0.18 |
| 2025-11-26 | 0.18 |
| 2025-11-25 | 0.18 |
| 2025-11-24 | 0.18 |
| 2025-11-21 | 0.18 |
| 2025-11-20 | 0.18 |
| 2025-11-19 | 0.18 |
| 2025-11-18 | 0.18 |
| 2025-11-17 | 0.18 |
| 2025-11-14 | 0.18 |
| 2025-11-13 | 0.18 |
| 2025-11-12 | 0.18 |
| 2025-11-11 | 0.18 |
| 2025-11-10 | 0.18 |
| 2025-11-07 | 0.18 |
| 2025-11-06 | 0.18 |
| 2025-11-05 | 0.18 |
| 2025-11-04 | 0.18 |
| 2025-11-03 | 0.18 |
| 2025-10-31 | 0.18 |
| 2025-10-30 | 0.18 |
| 2025-10-29 | 0.18 |
| 2025-10-28 | 0.18 |
| 2025-10-27 | 0.18 |
| 2025-10-24 | 0.18 |
| 2025-10-23 | 0.18 |
| 2025-10-22 | 0.18 |
| 2025-10-21 | 0.18 |
| 2025-10-20 | 0.18 |
| 2025-10-17 | 0.18 |
| 2025-10-16 | 0.18 |